SAN FRANCISCO, Nov. 1 /PRNewswire/ -- Data from six studies of PROCRIT(R) (Epoetin alfa) will be presented at the 40th annual meeting of the American Society of Nephrology (ASN) on November 2 - 5, 2007.
Several of these studies provide information on issues that have been the subject of recent scientific and regulatory discussions about appropriate use of erythropoiesis-stimulating agents (ESAs). These include data related to cardiovascular outcomes, hemoglobin stability, and hemoglobin response relative to ESA dosing in chronic renal failure (CRF) patients with anemia.
In some cases, the data are from investigational studies and do not reflect current Food and Drug Administration (FDA)-approved PROCRIT indications or recommended dosage and administration.
Please note that all information presented at the ASN is embargoed for media release until one hour after the time of presentation.
About PROCRIT (Epoetin alfa)
PROCRIT is indicated for the treatment of anemia in patients with most types of cancer receiving chemotherapy, with chronic renal failure who are on dialysis and those who are not on dialysis, who are being treated with zidovudine for HIV infection, and to reduce the need for transfusion in anemic patients who are scheduled for elective noncardiac, nonvascular surgery. Depending on the country in which Epoetin alfa is marketed, these indications may differ.
Contraindications
PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products.
Please visit www.procrit.com for the full Prescribing Information, including the Boxed Warning.
About Ortho Biotech Products, L.P.
Ortho Biotech Products, L.P. is a leading biopharmaceutical company devoted to helping improve the lives of patients with cancer and with anemia due to multiple causes, including chronic kidney disease. Since it was founded in 1990, Ortho Biotech and its worldwide affiliates have earned a global reputation for researching, manufacturing and marketing innovative products that enhance patients’ health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious illnesses. For more information, visit www.orthobiotech.com.
CONTACT: Stephanie Fagan, +1-908-541-4029 office, +1-201-572-9581 cell,
sfagan@obius.jnj.com
Web site: http://www.orthobiotech.com/